Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRTX NYSE:CCM NASDAQ:MGRX NASDAQ:MRAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRTXBiorestorative Therapies$0.41-2.2%$0.26$0.16▼$2.05$10.32M0.6730.62 million shs1.36 million shsCCMConcord Medical Services$4.74-6.4%$4.37$3.18▼$10.77$20.75M-0.9943,879 shs65,422 shsMGRXMangoceuticals$0.36-8.3%$0.40$0.16▼$2.75$6.13M2.27738,457 shs361,092 shsMRAIMarpai$0.57+1.8%$0.34$0.22▼$1.78$14.57M4.9464,473 shs2,036 shsThe Rise of the RobotsRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and industrial operations. This report explores the rise of “Physical AI,” highlights four key ways investors can gain exposure to the robotics revolution, and profiles seven leading companies positioned to benefit from the growing demand for intelligent automation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRTXBiorestorative Therapies-2.24%-12.53%+65.44%+90.23%-77.05%CCMConcord Medical Services-2.67%-4.80%-3.45%+24.63%-36.51%MGRXMangoceuticals-8.30%-16.98%+1.71%-4.29%-83.99%MRAIMarpai+1.79%-23.80%+111.11%+21.28%-57.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRTXBiorestorative Therapies$0.41-2.2%$0.26$0.16▼$2.05$10.32M0.6730.62 million shs1.36 million shsCCMConcord Medical Services$4.74-6.4%$4.37$3.18▼$10.77$20.75M-0.9943,879 shs65,422 shsMGRXMangoceuticals$0.36-8.3%$0.40$0.16▼$2.75$6.13M2.27738,457 shs361,092 shsMRAIMarpai$0.57+1.8%$0.34$0.22▼$1.78$14.57M4.9464,473 shs2,036 shsThe Rise of the RobotsRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and industrial operations. This report explores the rise of “Physical AI,” highlights four key ways investors can gain exposure to the robotics revolution, and profiles seven leading companies positioned to benefit from the growing demand for intelligent automation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRTXBiorestorative Therapies-2.24%-12.53%+65.44%+90.23%-77.05%CCMConcord Medical Services-2.67%-4.80%-3.45%+24.63%-36.51%MGRXMangoceuticals-8.30%-16.98%+1.71%-4.29%-83.99%MRAIMarpai+1.79%-23.80%+111.11%+21.28%-57.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRTXBiorestorative Therapies 1.00SellN/AN/ACCMConcord Medical Services 1.00SellN/AN/AMGRXMangoceuticals 1.00SellN/AN/AMRAIMarpai 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MGRX, CCM, MRAI, and BRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026BRTXBiorestorative Therapies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/26/2026CCMConcord Medical Services Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026MGRXMangoceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRTXBiorestorative Therapies$360K28.67N/AN/A$0.04 per share10.13CCMConcord Medical Services$65.85M0.31$1.84 per share2.57$60.94 per share0.08MGRXMangoceuticals$460K13.33N/AN/A$0.93 per share0.38MRAIMarpai$34.87M0.42N/AN/A($1.72) per share-0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRTXBiorestorative Therapies-$14.24M-$1.07N/AN/AN/A-3,088.27%-508.42%-230.94%8/11/2026 (Estimated)CCMConcord Medical Services-$13.27MN/AN/AN/AN/AN/AN/AN/AN/AMGRXMangoceuticals-$20.64M-$1.49N/AN/AN/A-4,639.13%-112.00%-104.96%N/AMRAIMarpai-$28.75M-$0.87N/AN/AN/A-85.70%N/A-100.23%8/12/2026 (Estimated)Latest MGRX, CCM, MRAI, and BRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026Q1 2026MGRXMangoceuticalsN/A-$0.22N/A-$0.22N/A$0.07 million5/14/2026Q1 2026BRTXBiorestorative Therapies-$0.20-$0.19+$0.01-$0.12$0.31 million$0.02 million4/29/2026Q4 2025CCMConcord Medical ServicesN/A-$1.08N/A-$1.08N/AN/A3/26/2026Q4 2025BRTXBiorestorative Therapies-$0.37-$0.37N/A-$0.32$0.15 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBRTXBiorestorative TherapiesN/AN/AN/AN/AN/ACCMConcord Medical ServicesN/AN/AN/AN/AN/AMGRXMangoceuticalsN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRTXBiorestorative TherapiesN/A2.352.35CCMConcord Medical Services1.330.480.46MGRXMangoceuticalsN/A0.290.29MRAIMarpaiN/A0.820.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRTXBiorestorative Therapies69.38%CCMConcord Medical ServicesN/AMGRXMangoceuticals56.72%MRAIMarpai49.75%Insider OwnershipCompanyInsider OwnershipBRTXBiorestorative Therapies13.60%CCMConcord Medical Services46.50%MGRXMangoceuticals16.00%MRAIMarpai46.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRTXBiorestorative Therapies725.48 million22.01 millionNot OptionableCCMConcord Medical Services9704.34 million2.32 millionNot OptionableMGRXMangoceuticals317.17 million14.42 millionNot OptionableMRAIMarpai15025.56 million5.61 millionNo DataMGRX, CCM, MRAI, and BRTX HeadlinesRecent News About These CompaniesMarpai (NASDAQ:MRAI) Trading Up 55.8% - What's Next?May 28, 2026 | americanbankingnews.comMarpai Inc. Announces Unprecedented Growth with 192,000 New Estimated Member Lives Across TPA and MarpaiRx PBM Platforms; Expects to Achieve Positive Cash Flow and EBITDA ...May 27, 2026 | tmcnet.comMarpai Inc. Announces Unprecedented Growth with 192,000 New Estimated Member Lives Across TPA and MarpaiRx PBM Platforms; Expects to Achieve Positive Cash Flow and EBITDA Beginning August 2026May 26, 2026 | prnewswire.comMARPAI REPORTS FIRST QUARTER 2026 FINANCIAL RESULTSMay 15, 2026 | prnewswire.comMarpai, Inc. Announces Significant New Business Wins across TPA and MarpaiRx; Solidifies Forecast for ProfitabilityMay 11, 2026 | prnewswire.comMarpai Extends Maturity of Insider Promissory NotesMay 1, 2026 | tipranks.comMarpai, Inc. Secures Major Strategic Marketing Collaboration to Continue Acceleration of MarpaiRx Growth NationwideApril 1, 2026 | prnewswire.comMarpai Secures Access to Network Creating Major Growth Catalyst for MarpaiRx Representing Up to 1.5 million Covered LivesMarch 9, 2026 | prnewswire.comMarpai, Inc. Secures Major Strategic Wins for MarpaiRx, Adding Over 19,000 Lives and Accelerating High-Growth Platform ExpansionFebruary 23, 2026 | prnewswire.comMARPAI, INC. HIRES PHARMACY EXECUTIVE MIMI DAVIS AS PRESIDENT OF MARPAIRX TO DRIVE STRATEGIC GROWTHJanuary 27, 2026 | prnewswire.comMarpai consolidates leadership as CEO Damien Lamendola becomes PresidentJanuary 23, 2026 | tipranks.comMARPAI ANNOUNCES 2026 MOMENTUM AND KEY PARTNERSHIP EXPANSIONDecember 1, 2025 | prnewswire.comMarpai, Inc. Earnings Call Highlights Mixed SentimentNovember 14, 2025 | msn.comMARPAI REPORTS THIRD QUARTER 2025 FINANCIAL RESULTSNovember 12, 2025 | prnewswire.comMarpai Signs Material Definitive AgreementNovember 12, 2025 | tipranks.comMARPAI TO HOST WEBCAST ON NOVEMBER 13, 2025 TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTSNovember 6, 2025 | prnewswire.comMarpai Authorizes 2 Million Blank-Check Preferred SharesOctober 21, 2025 | msn.comMarpai Announces Compliance with Securities Exchange ActOctober 19, 2025 | theglobeandmail.comMARPAI RECOGNIZED AS 2025 TOP THIRD PARTY ADMINISTRATOROctober 14, 2025 | prnewswire.comMARPAI, INC. RECEIVES ADDITIONAL $200,000 INVESTMENT FROM DAMIEN LAMENDOLA'S HILLCOUR INVESTMENT FUNDOctober 6, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGRX, CCM, MRAI, and BRTX Company DescriptionsBiorestorative Therapies NASDAQ:BRTX$0.40 -0.01 (-2.24%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.39 -0.02 (-3.70%) As of 06/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Concord Medical Services NYSE:CCM$4.74 -0.32 (-6.40%) Closing price 06/5/2026 03:59 PM EasternExtended Trading$4.81 +0.07 (+1.48%) As of 06/5/2026 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.Mangoceuticals NASDAQ:MGRX$0.36 -0.03 (-8.30%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.37 +0.01 (+3.64%) As of 06/5/2026 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.Marpai NASDAQ:MRAI$0.57 +0.01 (+1.79%) As of 06/5/2026 03:29 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
